Author

Amit Suresh Bhate

Observed names: A. Bhate, AMIT BHATE, Amit Suresh Bhate, Amit Bhate, Amit S Bhate, Amit S. Bhate, Amit Suresh Bhate

OpenAlex ID: A5007602589

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

2021 · Raches Ella, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 378

PDF

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

2021 · Raches Ella, Siddarth Reddy, et al. · The Lancet · 344

PDF

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)

2023 · Chandramani Singh, Savita Verma, et al. · npj Vaccines · 91

PDF

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

2023 · Gustavo H Dayan, Nadine Rouphael, et al. · The Lancet Respiratory Medicine · 25

PDF

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

2022 · Gustavo H. Dayan, Nadine Rouphael, et al. · medRxiv · 14

PDF

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

2023 · Gustavo H. Dayan, Nadine Rouphael, et al. · EClinicalMedicine · 11

Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial

2025 · Venkateshwar Rao Akula, Amit Suresh Bhate, et al. · Communications Medicine · 9

PDF

Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial

2023 · Chandramani Singh, Savita Verma, et al. · SSRN Electronic Journal · 7

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 6

PDF

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients

2025 · Chintan Patel, Vaishal Sheth, et al. · Respiratory Medicine · 1

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)

2024 · Prabhat K Agarwal, Divendu Bhushan, et al. · Clinical Diabetes and Endocrinology · 1

PDF

Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study)

2024 · SHANTANU SENGUPTA, JAYAGOPAL PATHIYILBALAGOPALAN, et al. · Journal of Cardiac Failure · 1

Safety and Effectiveness of Indacaterol/Glycopyrronium/Mometasone Dry Powder Inhaler in Asthma: A Prospective Multicenter Phase IV Study

2026 · Saurabh Karmakar, Amit S Bhate, et al. · Journal of the Association of Physicians of India

Efficacy and Safety of Vilanterol/Umeclidinium Fixed-Dose Combination versus Vilanterol/Glycopyrronium Delivered via Metered-Dose and Dry-Powder Inhalers in Indian Adults with COPD: Two Independent, Platform-Matched Phase III Randomized, Active-Controlled Non-Inferiority Trials

2026 · Pankaj Bharat Bhai Vyas, Mitul Kumar Manubhai Chaudhari, et al. · SSRN Electronic Journal

Effectiveness and Safety of Glycopyrronium–Formoterol–Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study

2025 · Anjali R. Nath, Adesh Kumar, et al. · Advances in respiratory medicine

PDF

Prospective, Open-Label, Observational, Multicenter, Single Arm, Post-Marketing Study in Asthmatic Patients for Evaluation of Safety and Effectiveness of Indacaterol/Mometasone DPI (PROMISING-SHIFT)

2025 · Saurabh Karmakar, Gajendra V. Singh, et al. · Advances in respiratory medicine

Studying the trend of HbA1C changes with NYHA class with SGLT2i in HFrEF T2DM Indian patients - A post-hoc analysis of REMIT-HF

2024 · Shantanu Sengupta, Rahee Borulkar, et al. · Indian Heart Journal

Works count: 17

Citation count: 888

H-index: 7

I10-index: 6